CalciMedica (CALC) CMO awarded 91,173 options at $0.585 exercise price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
CalciMedica, Inc. reported that Chief Medical Officer Sudarshan Hebbar received an employee stock option grant covering 91,173 shares of common stock with an exercise price of $0.585 per share. All 91,173 options are held directly after this grant.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years, and no shares vest until the company files a Form S-8 covering shares added under its 2023 Equity Incentive Plan evergreen provision.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hebbar Sudarshan
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 91,173 | $0.00 | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 91,173 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 91,173 options
Exercise price: $0.585 per share
Post-transaction derivative holdings: 91,173 options
+3 more
6 metrics
Option grant size
91,173 options
Employee stock option grant to CMO Sudarshan Hebbar
Exercise price
$0.585 per share
Exercise price for the 91,173 option shares
Post-transaction derivative holdings
91,173 options
Total options directly held after the reported grant
Vesting start date
April 1, 2026
1/48th of the option shares vest monthly from this date
Vesting schedule
1/48th monthly over 4 years
Equal monthly installments across four years after vesting start
Option expiration
April 4, 2036
Expiration date for the employee stock option
Key Terms
Employee Stock Option (Right to Buy), Form S-8, 2023 Equity Incentive Plan, evergreen provision, +1 more
5 terms
Employee Stock Option (Right to Buy) financial
"security_title: "Employee Stock Option (Right to Buy)""
Form S-8 regulatory
"until the filing of the Company's registration statement on Form S-8 covering the shares"
A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.
2023 Equity Incentive Plan financial
"authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026"
evergreen provision financial
"added to the shares authorized for issuance ... pursuant to an annual "evergreen" provision"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
derivative security financial
"transaction_type: "derivative" for the stock option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did CalciMedica (CALC) disclose about Sudarshan Hebbar in this Form 4?
CalciMedica disclosed that Chief Medical Officer Sudarshan Hebbar received an employee stock option grant for 91,173 shares of common stock at a $0.585 exercise price. These options are held directly and represent a compensation-related award, not an open-market stock purchase or sale.
How many CalciMedica (CALC) options did Sudarshan Hebbar receive and at what price?
Sudarshan Hebbar received an employee stock option covering 91,173 shares of CalciMedica common stock with a $0.585 per-share exercise price. This grant is recorded as a derivative security, giving the right to buy common shares at that fixed exercise price in the future, subject to vesting.
When do Sudarshan Hebbar’s CalciMedica (CALC) options start vesting and over what period?
Vesting starts on April 1, 2026, when 1/48th of the option shares vest monthly over four years. The schedule provides gradual vesting, aligning the award with long-term service. However, no shares vest until certain Form S-8 conditions for the company’s 2023 Equity Incentive Plan are met.
Is Sudarshan Hebbar’s CalciMedica (CALC) Form 4 transaction a market buy or sell?
The Form 4 reports a grant of employee stock options, not a market buy or sell of common shares. The transaction is coded as an acquisition (A) for 91,173 derivative securities, reflecting a compensation-related award rather than an open-market trade in CalciMedica stock.
What condition affects vesting of Sudarshan Hebbar’s CalciMedica (CALC) options?
No shares under the option will vest until CalciMedica files a registration statement on Form S-8. That Form S-8 must cover common shares automatically added on January 1, 2026 to the 2023 Equity Incentive Plan under its annual evergreen provision, according to the footnote disclosure.
How many CalciMedica (CALC) options does Sudarshan Hebbar hold after this transaction?
After this transaction, Sudarshan Hebbar directly holds 91,173 employee stock options linked to CalciMedica common stock. This total equals the size of the new grant, indicating these options constitute his reported derivative holdings in this filing, all subject to the described vesting and plan conditions.